Supernus’ stocks down again, despite positive phase 3 ADHD data by Conor Hale Thursday, December 6, 2018 Supernus’ two phase 3 studies in children with ADHD hit their primary endpoints but didn’t wow investors worried about established generics.
Supernus adds epilepsy drug via $185M Biscayne buy by Phil Taylor Friday, September 14, 2018 Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
Supernus clears PhII ADHD drug hurdle, but shares drip downward by Ben Adams Tuesday, October 11, 2016 Specialty pharma Supernus has posted positive data from its childhood ADHD midstage test as it looks to start Phase III trials next year--but its shares ticked down as some decided to “sell the news” instead of buying into it.
